Story
Pyxis Oncology Shares Decline After Announcing Public Stock Offering
Summary
The clinical-stage biopharmaceutical company saw its stock fall 3.5% in after-hours trading following its announcement of a planned offering of common stock and warrants to raise capital. Proceeds are intended to fund the advancement of its lead drug candidate.
Shares of Pyxis Oncology (NASDAQ:PYXS) fell 3.5% in after-hours trading Tuesday after the company announced plans for a registered public offering of common stock and warrants. The move is a common strategy for clinical-stage biotech firms to raise capital for research and development.
Details of the Offering
Pyxis Oncology said it intends to offer shares of its common stock, or pre-funded warrants in lieu of common stock for certain investors, according to a company statement. The offering will also include accompanying common warrants to purchase additional shares. The company has not yet disclosed the size or pricing terms of the deal.
The offering is being managed by a syndicate of banks, with Leerink Partners, Guggenheim Securities, and Wells Fargo Securities acting as joint bookrunning managers. Completion of the offering is contingent upon market conditions and other factors, with no assurance as to when or if it will be finalized.
Use of Proceeds and Market Impact
Pyxis Oncology plans to use the net proceeds to advance its lead clinical program, an antibody-drug conjugate named micvotabart pelidotin. The funding is specifically earmarked for key clinical milestones, including its planned Phase 3 trial, dubbed "Headliner," for treating head and neck squamous cell carcinoma.
AdThe drop in the company's stock price following the announcement is a typical market reaction. Such offerings can lead to share dilution, where the issuance of new stock decreases the ownership percentage of existing shareholders, often placing short-term downward pressure on the share price.
Warrant Conditions
A key provision of the offering is that the common warrants will only become exercisable after the company's stockholders approve an amendment to increase the number of authorized shares of common stock.
The warrants are set to expire upon the earlier of two events: the fifth anniversary of the charter amendment's effective date, or 30 days after the company discloses overall survival data from its Phase 1 study of micvotabart pelidotin. The company noted that it expects to release this data in the first half of 2027.
Read next
More on Stocks
Brazil's Bovespa Index Gains 0.46% on Sector Strength Despite Rising Volatility
Brazil's benchmark stock index closed higher on Tuesday, supported by gains in the real estate and financial sectors, even as an index measuring market volatility surged to a three-year high.
4D Molecular Therapeutics Named Top Biotech Pick by B. Riley on Gene Therapy Promise
B. Riley Securities reiterated its Buy rating and $37 price target on 4D Molecular Therapeutics, citing the launch of a key Phase 3 trial and promising long-term data for its eye disease gene therapy, 4D-150.
S&P Upgrades Wells Fargo to 'A-' on Risk Management Progress
S&P Global Ratings has raised Wells Fargo's long-term credit rating, citing significant improvements in governance and risk oversight following the removal of a long-standing Federal Reserve asset cap.
Evercore ISI Names Top Airline Picks as Fuel Volatility Challenges Sector
Investment firm Evercore ISI has identified its top airline stock selections, including Delta and United, as the industry navigates a combination of strong travel demand and extreme jet fuel price volatility.